Patents by Inventor Kenneth Ellsworth
Kenneth Ellsworth has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230287141Abstract: Antibodies that bind the apple 3 domain of human coagulation Factor XI and inhibit activation of FXI by coagulation factor XIIa as well as activation of FIX by FXIa are described.Type: ApplicationFiled: April 18, 2023Publication date: September 14, 2023Applicants: Merck Sharp & Dohme LLC, Adimab, LLCInventors: Zhu Chen, Kenneth Ellsworth, James Milligan, Elizabeth Oldham, Dietmar Seiffert, Bianka Prinz, Vaishnavi Ganti, Mohammad Tabrizifard
-
Patent number: 11661460Abstract: Antibodies that bind the apple 3 domain of human coagulation Factor XI and inhibit activation of FXI by coagulation factor XIIa as well as activation of FIX by FXIa are described.Type: GrantFiled: May 1, 2020Date of Patent: May 30, 2023Assignees: Merck Sharp & Dohme LLC, Adimab, LLCInventors: Zhu Chen, Kenneth Ellsworth, James Milligan, Elizabeth Oldham, Dietmar Seiffert, Vaishnavi Ganti, Mohammad Tabrizifard, Bianka Prinz
-
Patent number: 11512142Abstract: Antibodies that bind the apple 3 domain of human coagulation Factor XI and inhibit activation of FXI by coagulation factor XIIa as well as activation of FIX by FXIa are described.Type: GrantFiled: May 1, 2020Date of Patent: November 29, 2022Assignees: Merck Sharp & Dohme LLC, Adimab LLCInventors: Zhu Chen, Kenneth Ellsworth, James Milligan, Elizabeth Oldham, Dietmar Seiffert, Bianka Prinz
-
Patent number: 11485794Abstract: Antibodies that bind the apple 3 domain of human coagulation Factor XI and inhibit activation of FXI by coagulation factor XIIa as well as activation of FIX by FXIa are described.Type: GrantFiled: May 1, 2020Date of Patent: November 1, 2022Assignees: Merck Sharp & Dohme LLC, Adimab, LLCInventors: Zhu Chen, Kenneth Ellsworth, James Milligan, Elizabeth Oldham, Dietmar Seiffert, Bianka Prinz
-
Patent number: 11479615Abstract: Antibodies that bind the apple 3 domain of human coagulation Factor XI and inhibit activation of FXI by coagulation factor XIIa as well as activation of FIX by FXIa are described.Type: GrantFiled: May 1, 2020Date of Patent: October 25, 2022Assignees: Merck Sharp & Dohme LLC, Adimab, LLCInventors: Zhu Chen, Kenneth Ellsworth, James Milligan, Elizabeth Oldham, Dietmar Seiffert, Bianka Prinz
-
Publication number: 20220235033Abstract: The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XI activation inhibitors.Type: ApplicationFiled: May 26, 2020Publication date: July 28, 2022Applicant: Merck Sharp & Dohme Corp.Inventors: Jacqueline D. Hicks, John S. Debenham, Amjad Ali, Lan Wei, Tianying Jian, Dexi Yang, Anthony K. Ogawa, Wenlang Fu, Matthew Lombardo, Rongze Kuang, Meng Yang, Sung-Sau So, Kenneth Ellsworth, Peter Nizner, Daniel A. Tatosian, Robert R. Wilkening, Jun Wang
-
Publication number: 20200317811Abstract: Antibodies that bind the apple 3 domain of human coagulation Factor XI and inhibit activation of FXI by coagulation factor XIIa as well as activation of FIX by FXIa are described.Type: ApplicationFiled: May 1, 2020Publication date: October 8, 2020Applicants: Merck Sharp & Dohme Corp., Adimab, LLCInventors: Zhu Chen, Kenneth Ellsworth, James Milligan, Elizabeth Oldham, Dietmar Seiffert, Vaishnavi Ganti, Mohammad Tabrizifard, Bianka Prinz
-
Publication number: 20200308302Abstract: Antibodies that bind the apple 3 domain of human coagulation Factor XI and inhibit activation of FXI by coagulation factor XIIa as well as activation of FIX by FXIa are described.Type: ApplicationFiled: May 1, 2020Publication date: October 1, 2020Applicants: Merck Sharp & Dohme Corp., Adimab, LLCInventors: Zhu Chen, Kenneth Ellsworth, James Milligan, Elizabeth Oldham, Dietmar Seiffert, Vaishnavi Ganti, Mohammad Tabrizifard, Bianka Prinz
-
Publication number: 20200270364Abstract: Antibodies that bind the apple 3 domain of human coagulation Factor XI and inhibit activation of FXI by coagulation factor XIIa as well as activation of FIX by FXIa are described.Type: ApplicationFiled: May 1, 2020Publication date: August 27, 2020Applicants: Merck Sharp & Dohme Corp., Adimab, LLCInventors: Zhu Chen, Kenneth Ellsworth, James Milligan, Elizabeth Oldham, Dietmar Seiffert, Vaishnavi Ganti, Mohammad Tabrizifard, Bianka Prinz
-
Publication number: 20200255542Abstract: Antibodies that bind the apple 3 domain of human coagulation Factor XI and inhibit activation of FXI by coagulation factor XIIa as well as activation of FIX by FXIa are described.Type: ApplicationFiled: May 1, 2020Publication date: August 13, 2020Applicants: Merck Sharp & Dohme Corp., Adimab, LLCInventors: Zhu Chen, Kenneth Ellsworth, James Milligan, Elizabeth Oldham, Dietmar Seiffert, Vaishnavi Ganti, Mohammad Tabrizifard, Bianka Prinz
-
Patent number: 10676536Abstract: Antibodies that bind the apple 3 domain of human coagulation Factor XI and inhibit activation of FXI by coagulation factor XIIa as well as activation of FIX by FXIa are described.Type: GrantFiled: June 12, 2017Date of Patent: June 9, 2020Assignees: Merck Sharp & Dohme Corp., ADIMAB, LLCInventors: Zhu Chen, Kenneth Ellsworth, James Milligan, Elizabeth Oldham, Dietmar Seiffert, Bianka Prinz
-
Publication number: 20180362661Abstract: Antibodies that bind the apple 2 domain of human coagulation Factor XI and inhibit activation of FXI by coagulation factor XIIa are described.Type: ApplicationFiled: August 13, 2018Publication date: December 20, 2018Applicants: Merck Sharp & Dohme Corp,, Adimab, LLCInventors: Zhu Chen, Kenneth Ellsworth, James A. Milligan, Elizabeth Oldham, Dietmar Seiffert, Vaishnavi Ganti, Mohammad Tabritzifard, Bianka Prinz
-
Publication number: 20170355780Abstract: Antibodies that bind the apple 3 domain of human coagulation Factor XI and inhibit activation of FXI by coagulation factor XIIa as well as activation of FIX by FXIa are described.Type: ApplicationFiled: June 12, 2017Publication date: December 14, 2017Applicant: Merck Sharp & Dohme Corp.Inventors: Zhu Chen, Kenneth Ellsworth, James Milligan, Elizabeth Oldham, Dietmar Seiffert, Vaishnavi Ganti, Mohammad Tabrizifard
-
Patent number: 5912427Abstract: This invention discloses a method of fabricating an electroexplosive device which utilizes a semiconductor bridge as an ignition element. The semiconductor bridge is electrically connected to a metal header by a small, low resistance contact to the extension of bridge material and through an insulating silicon substrate to an eutectic bond created by gold plating on the metal header and the silicon. The second electrode of the bridge circuit is connected via wire bonds to one or two conducting pins which penetrate the metal header and are insulated by surrounding glass. A redundant connection via two conducting pins insulated from the header to one electrode of the semiconductor bridge allows a post assembly test of the integrity of the wire bonds, thereby increasing reliability of the device.Type: GrantFiled: January 31, 1995Date of Patent: June 15, 1999Assignee: Quantic Industries, Inc.Inventors: Kenneth Ellsworth Willis, Martin Gerald Richman, William David Fahey, John Gareth Richards, David S. Whang
-
Patent number: 4498096Abstract: An axial lead semiconductor device package is provided for use with non-planar semiconductor die. By using solders of predetermined strength, wetting and flow characteristics, melting temperature, shape, area, and thickness, reliable attachment of non-planar die to planar mounting surfaces is achieved.Type: GrantFiled: September 12, 1983Date of Patent: February 5, 1985Assignee: Motorola, Inc.Inventors: David L. Addie, Kenneth A. Ellsworth
